Want to see AU:HLS full AI Analyst Report?
HLS Stock Chart & Stats
AU$0.44
<AU$0.01(1.45%)
At close: 4:00 PM EDT
AU$0.44
<AU$0.01(1.45%)
Day’s Range― - ―
52-Week RangeAU$0.30 - AU$1.07
Previous CloseN/A
Volume1.06M
Average Volume (3M)6.85M
Market Cap
AU$283.21M
Enterprise ValueAU$1.21B
Total Cash (Recent Filing)AU$67.20M
Total Debt (Recent Filing)AU$998.70M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Feb 24, 2027EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend Yield35.6%
Share Statistics
EPS (TTM)-0.57
Shares Outstanding726,178,800
10 Day Avg. Volume3,056,425
30 Day Avg. Volume6,852,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.65
Price to Sales (P/S)0.21
P/FCF Ratio1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.45Price Target Upside3.18% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.40B
Bulls Say, Bears Say
Bulls Say
Persistent Free Cash FlowPersistent positive operating and free cash flow, including during recent loss-making years, indicates the diagnostic network is still converting activity into liquidity. The FY2026 improvement can support debt reduction and ongoing operations, although historical variability means cash generation is not fully consistent.
Deleveraging ProgressMeaningful debt reduction improves financial flexibility and lowers the balance-sheet burden carried by the business. This progress, together with positive free cash flow, may give Healius greater capacity to manage obligations and fund operations despite continuing earnings pressure.
Revenue RecoveryThe FY2026 revenue rebound shows that the underlying pathology and diagnostic imaging network can recover after a period of contraction. Restored top-line scale can improve operating leverage and provide a foundation for better earnings if service volumes and cost control remain supportive.
Bears Say
Sustained Net LossesFour consecutive years of net losses indicate that revenue recovery has not yet translated into durable shareholder profitability. Continued losses can constrain reinvestment, weaken equity, and make the business more dependent on cash generation and balance-sheet actions to sustain financial flexibility.
Unstable Operating MarginsUnstable and recently thin operating margins suggest that the cost base is not consistently absorbing revenue at an attractive level. This reduces confidence that the FY2026 top-line recovery will produce sustained earnings improvement and leaves results vulnerable to further margin deterioration.
Contracted Equity And Weak ReturnsA substantially smaller equity base and deeply negative recent returns weaken the company’s financial foundation. Even with lower debt, reduced equity limits balance-sheet resilience and leaves less capacity to absorb ongoing losses or support future investment without additional pressure.
Healius Limited News
HLS FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest share price was AU$0.30 and its highest was AU$1.07 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is AU$283.21M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Feb 24, 2027 which is in 124 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Aug 18, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.001 by -AU$0.004.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited pays a Notavailable dividend of AU$0.413 which represents an annual dividend yield of 35.6%. See more information on Healius Limited dividends here
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is -0.01.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,178,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.001. Following the earnings report the stock price went down -5.618%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in AU:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.45 (3.18% Upside)
AU$0.45 (3.18% Upside)
Blogger Sentiment
Bullish
AU:HLS Sentiment 93%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-114.08%
Trailing 12-Months
Asset Growth
-13.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Healius Limited
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
HLS Stock 12 Month Forecast
Average Price Target
AU$0.45
▲(3.18% Upside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―